Management of Porto-systemic Shunts (Congenital & Acquired)

Sunday, March 5, 2023

8:30 AM – 10:00 AM

Location:Phoenix Convention Center, 224AB

CE: 1.5 Credits

Coordinator(s)

Sanjeeva Kalva, MD, FSIR, FCIRSE, FACR (he/him/his)

Professor
Massachusetts General Hospital

Disclosure(s): BD Bard: Consultant (Ongoing); Biogen Inc, Clover Health Investments Corp, Inovio Pharmaceuticals, Moderna Inc, Pfizer Inc, Novavax Inc, Orphazyme, Cassava Sciences Inc, Vivos Therapeutics Inc, Ardelyx Inc, Althea Health, Sarepta Therapeutics, Clover Health Investments Corp, CureV: Ownership Interest (Ongoing), Stocks (Ongoing); Boston Scientific Corp: Consultant (Ongoing); Canon Medical: Consultant (Ongoing), Speaking and Teaching (Ongoing); Covidien/Medtronic: Consultant (Ongoing); Instylla, Inc.: Consultant (Ongoing); Okami Medical: Consultant (Ongoing); Penumbra Inc.: Consultant (Terminated), Speaking and Teaching (Terminated); Sirtex Medical: Consultant (Ongoing); Varian: Consultant (Ongoing)
Maria del Pilar Bayona Molano, MD

Associate Professor
UT Southwestern Medical center

Disclosure(s): No financial relationships to disclose

Disclosure(s):

Sanjeeva Kalva, MD, FSIR, FCIRSE, FACR: BD Bard: Consultant (Ongoing); Biogen Inc, Clover Health Investments Corp, Inovio Pharmaceuticals, Moderna Inc, Pfizer Inc, Novavax Inc, Orphazyme, Cassava Sciences Inc, Vivos Therapeutics Inc, Ardelyx Inc, Althea Health, Sarepta Therapeutics, Clover Health Investments Corp, CureV: Ownership Interest (Ongoing), Stocks (Ongoing); Boston Scientific Corp: Consultant (Ongoing); Canon Medical: Consultant (Ongoing), Speaking and Teaching (Ongoing); Covidien/Medtronic: Consultant (Ongoing); Instylla, Inc.: Consultant (Ongoing); Okami Medical: Consultant (Ongoing); Penumbra Inc.: Consultant (Terminated), Speaking and Teaching (Terminated); Sirtex Medical: Consultant (Ongoing); Varian: Consultant (Ongoing)

Maria del Pilar Bayona Molano, MD: No financial relationships to disclose

Congenital and acquired portosystemic shunts present with significant morbidity and are often misdiagnosed unless associated with cirrhosis. Patients may present with confusion, forgetfulness, cardiac failure and hepatic encephalopathy. Embolization remains the treatment of choice, but physiological consequences of embolotheraphy on the portal system need be considered. This session provides an in-depth review of etiology, clinical presentation, pathophysiology, imaging, the role of embolization and TIPS.

Learning Objectives:

Upon completition, the audience will be able to define the clinical relevance of portosystemic shunts and the complications associated in cirrhotic and non-cirrhotic patients.
The participant will learn and describe multiple treatment alternatives for congenital and acquired portosystemic shunts. The main focus will be interventional techniques and differentent approaches.
Describe data-supported outcomes of interventional therapies for portosystemic shunts.

Presentations:

8:30 AM – 8:43 AM

Mesenteric-gonadal Shunts
Speaker: Sanjeeva Kalva, MD, FSIR, FCIRSE, FACR (he/him/his) – Massachusetts General Hospital
8:43 AM – 8:56 AM

Pathophysiology of portosystemic shunts: Consequences of embolotherapy, Role of TIPS
Speaker: Maria del Pilar Bayona Molano, MD – UT Southwestern Medical center
8:56 AM – 9:09 AM

Congenital intrahepatic portosystemic shunts (including Abernathy)
Speaker: Shellie Josephs, MD – Stanford
9:09 AM – 9:22 AM

Clinical presentation, Diagnosis and Imaging findings of Congenital and Acquired portosystemic shunts
Speaker: Harold Park, MD, MS, RPVI – UC Irvine
9:22 AM – 9:35 AM

Other Shunts: Umbilical, Rectal-iliac shunts
Speaker: Paula Novelli, MD FSIR – University of Pittsburgh Medical Center
9:35 AM – 9:48 AM

Gastro-renal shunt Embolization
Speaker: Amar Mukund, MBBS, MD – Institute of Liver and Biliary Sciences
9:48 AM – 10:00 AM

Q & A